Atumelnant

Atumelnant is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone -dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor, also known as the ACTH receptor, which is primarily expressed in the adrenal glands. The drug is orally active. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.